SEARCH

SEARCH BY CITATION

References

  • Avet-Loiseau, H., Li, J.Y., Facon, T., Brigaudeau, C., Morineau, N., Maloisel, F., Rapp, M.J., Talmant, P., Trimoreau, F., Jaccard, A., Harousseau, J.L. & Bataille, R. (1998) High incidence of translocations t(11;14) (q13;q32) and t(4;14) (p16;q32) in patients with plasma cell malignancies. Cancer Research, 58, 56405645.
  • Avet-Loiseau, H., Brigaudeau, C., Morineau, N., Talmant, P., Lai, J.L., Daviet, A., Li, J.Y., Praloran, V., Rapp, M.J., Harousseau, J.L., Facon, T. & Bataille, R. (1999) High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes, Chromosomes and Cancer, 24, 915.DOI: 10.1002/(sici)1098-2264(199901)24:1<9::aid-gcc2>3.3.co;2-b
  • Barlogie, B., Alexanian, R., Pershouse, M., Smallwood, L. & Smith, L. (1985) Cytoplasmic immunoglobulin content in multiple myeloma. Journal of Clinical Investigation, 76, 765769.
  • Bartl, R., Frisch, B., Fateh-Moghadam, A., Kettner, G., Jaeger, K. & Sommerfeld, W. (1987) Histologic classification and staging of multiple myeloma. American Journal of Clinical Pathology, 87, 342355.
  • Brynes, R., McCourty, A., Tamayo, R., Jenkins, K. & Battifora, H. (1997) Demonstration of cyclin D1 (bcl-1) in mantle cell lymphoma: enhanced staining using heat and ultrasound epitope retrieval. Applied Immunohistochemistry, 5, 4548.
  • Chellappan, S.P., Hiebert, S., Mudryj, M., Horowitz, J.M. & Nevins, J.R. (1991) The E2F transcription factor is a cellular target for the RB protein. Cell, 65, 10531061.
  • Falini, B., Canino, S., Sacchi, S., Ciani, C., Martelli, M.F., Gerdes, J., Stein, H., Pileri, S., Gobbi, M., Fagioli, M., Minelli, O. & Flenghi, L. (1988) Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. British Journal of Haematology, 69, 311320.
  • Ffrench, M., Ffrench, P., Remy, F., Chapuis-Cellier, C., Wolowiec, D., Ville, D. & Bryon, P.A. (1995) Plasma cell proliferation in monoclonal gammopathy: relations with other biologic variables – diagnostic and prognostic significance. American Journal of Medicine, 98, 6066.
  • Fonseca, R., Hoyer, J.D., Aguayo, P., Jalal, S.M., Ahmann, G.J., Rajkumar, S., Witzig, T.E., Lacy, M.Q., Dispenzieri, A., Gertz, M.A., Kyle, R.A. & Greipp, P.R. (1999) Clinical significance of the translocation (11;14) (q13;q32) in multiple myeloma. Leukemia and Lymphoma, 35, 599605.
  • Greipp, P.R., Witzig, T.E., Gonchoroff, N.J., Habermann, T.M., Katzmann, J.A., O'Fallon, W.M. & Kyle, R.A. (1987) Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Proceedings of the Mayo Clinic, 62, 969977.
  • Hallek, M., Bergsagel, P.L. & Anderson, K.C. (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 321.
  • Hirama, T. & Koeffler, H.P. (1995) Role of cyclin-dependent kinase inhibitors in the development of cancer. Blood, 86, 841854.
  • Hunter, T. & Pines, J. (1994) Cyclins and cancer II: cyclin D and cdk inhibitors come of age. Cell, 79, 573582.
  • ISCN (1995) Guidelines for Cancer Cytogenetics, Supplement to an International System for Human Cytogenetic Nomenclature, (ed. by F.Mitelman). Karger, Basel, Switzerland.
  • Janssen, J.W.G., Vaandrager, J.-W., Heuser, T., Jauch, A., Kluin, P.M., Geelen, E., Bergsagel, P.L., Kuehl, W.M., Drexler, H.G., Otsuki, T., Bartram, C.R. & Schuuring, E. (2000) Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14) (q13;q32). Blood, 95, 26912698.
  • Johnson, D.G., Schwarz, J.K., Cress, W.D. & Nevins, J.R. (1993) Expression of the transcription factor E2F1 induces quiescent cells to enter S phase. Nature, 365, 349352.
  • Joshua, D., Petersen, A., Brown, R., Pope, B., Snowdon, L. & Gibson, J. (1996) The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. British Journal of Haematology, 94, 7681.
  • Kawano, M.M., Mahmoud, M.S. & Ishikawa, H. (1997) Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively. British Journal of Haematology, 99, 131138.
  • Kobayashi, H., Saito, H., Kitano, K., Kiyosawa, K., Gaun, S., Aoki, K., Narita, A., Watanabe, M., Uchimaru, K. & Motokura, T. (1995) Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14) (q13;q32). Acta Haematologica, 94, 199203.
  • Lai, J.L., Zandecki, M., Mary, J.Y., Bernardi, F., Izydorczyk, V., Flactif, M., Morel, P., Jouet, J.P., Bauters, F. & Facon, T. (1995) Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood, 85, 24902497.
  • Lai, R., Medeiros, L.J., Wilson, C.S., Sun, N.C.J., Koo, C., McCourty, A. & Brynes, R.K. (1998) Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf−1, and Ki-67 in multiple myeloma: correlation with cyclin D1 immunoreactivity. Modern Pathology, 11, 642647.
  • Motokura, T. & Arnold, A. (1993) Cyclins and oncogenesis. Biochimica et Biophysica Acta, 1155, 6378.
  • Ng, M.H.L., Chung, Y.F., Lo, K.W., Wickham, N.W.R., Lee, J.C.K. & Huang, D.P. (1997) Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood, 89, 25002506.
  • Nishida, K., Tamura, A., Nadazawa, N., Ueda, Y., Abe, T., Matsuda, F., Kashima, K. & Taniwaki, M. (1997) The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood, 90, 526534.
  • Reed, S.I. (1997) Control of the G1/S transition. Cancer Surveys, 29, 723.
  • Sato, M., Yamamoto, K., Iida, S., Akao, Y., Utsumi, K.R., Kubonishi, I., Miyoshi, I., Ohtsuki, T., Yawata, Y., Namba, M., Motokura, T., Arnold, A., Takahashi, T. & Ueda, R. (1992) Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14) (q13;32) translocation. Oncogene, 7, 14011406.
  • Sawyer, J.R., Waldron, J.A., Jagannath, S. & Barlogie. B. (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics, 82, 4149.DOI: 10.1016/0165-4608(94)00284-i
  • Sawyer, J.R., Lukacs, J.L., Munshi, N., Desikan, K.R., Singhal, S., Mehta, J., Siegel, D., . Shaughnessy, J. & Barlogie, B. (1998) Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood, 92, 42694278.
  • Shackney, S.E. & Shankey, T.V. (1999) Cell cycle models for molecular biology and molecular oncology: exploring new dimensions. Cytometry, 35, 97116.DOI: 10.1002/(sici)1097-0320(19990201)35:2<97::aid-cyto1>3.0.co;2-5
  • Sherr, C.J. (1996) Cancer cell cycles. Science, 274, 16721677.DOI: 10.1126/science.274.5293.1672
  • Sonoki, T., Hata, H., Kuribayashi, N., Yoshida, M., Harada, N., Nagasaki, A., Kimura, T., Matsuno, F., Mitsuya, H. & Matsuzaki, H. (1999) Expression of PRAD1/cyclin D1 in plasma cell malignancy: incidence and prognostic aspects. British Journal of Haematology, 104, 614617.
  • Tasaka, T., Berenson, J., Vescio, R., Hirama, T., Miller, C.W., Nagai, M., Takahara, J. & Koeffler, H.P. (1997) Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma. British Journal of Haematology, 96, 98102.
  • Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D.H., Naucke, S. & Sawyer, J.R. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86, 42504256.
  • Tricot, G., Sawyer, J.R., Jagannath, S., Desikan, K.R., Siegel, D., Naucke, S., Mattox, S., Bracy, D., Munshi, N. & Barlogie, B. (1997) Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. Journal of Clinical Oncology, 15, 26592666.
  • Tsurusawa, M., Aoyama, M., Saeki, K. & Fujimoto, T. (1995) Cell cycle kinetics in childhood acute leukemia studied with in vitro bromodeoxyuridine labeling, Ki67-reactivity and flow cytometry. Leukemia, 9, 19211925.
  • Urashima, M., Teoh, G., Ogata, A., Chauhan, D., Treon, S.P., Hoshi, Y., DeCaprio, J.A. & Anderson, K.C. (1997) Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma. Leukemia, 11, 19571963.
  • Vasef, M.A., Medeiros, L.J., Yospur, L.S., Sun, N.C.J., McCourty, A. & Brynes, R.K. (1997) Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Modern Pathology, 10, 927932.
  • Waldron, J., Jazieh, R., Jagannath, S., Desikan, K.R., Siegel, D., Fassas, A., Singhal, S., Mehta, J., Tricot, G., Vesole, D., Wilson, C., Hough, A., Naucke, S., Spoon, D. & Barlogie, B. (1997) Bone marrow morphology (BMM) adds critical prognostic information to other standard parameters (SP) including cytogenetics among newly diagnosed multiple myeloma (MM) patients (PTS) receiving total therapy (TT). Blood, 90, 90a(Abstract).
  • Weinberg, R.A. (1995) The retinoblastoma protein and cell cycle control. Cell, 81, 323330.